Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
Ta-Wei Tai,Hsuan-Yu Chen,Chien-An Shih,Chun-Feng Huang,Eugene McCloskey,Joon-Kiong Lee,Swan Sim Yeap,Ching-Lung Cheung,Natthinee Charatcharoenwitthaya,Unnop Jaisamrarn,Vilai Kuptniratsaikul,Rong-Sen Yang,Sung-Yen Lin,Akira Taguchi,Satoshi Mori,Julie Li-Yu,Seng Bin Ang,Ding-Cheng Chan,Wai Sin Chan,Hou Ng,Jung-Fu Chen,Shih-Te Tu,Hai-Hua Chuang,Yin-Fan Chang,Fang-Ping Chen,Keh-Sung Tsai,Peter R Ebeling,Fernando Marin,Francisco Javier Nistal Rodríguez,Huipeng Shi,Kyu Ri Hwang,Kwang-Kyoun Kim,Yoon-Sok Chung,Ian R Reid,Manju Chandran,Serge Ferrari,E Michael Lewiecki,Fen Lee Hew,Lan T Ho-Pham,Tuan Van Nguyen,Van Hy Nguyen,Sarath Lekamwasam,Dipendra Pandey,Sanjay Bhadada,Chung-Hwan Chen,Jawl-Shan Hwang,Chih-Hsing Wu
DOI: https://doi.org/10.1016/j.afos.2024.02.001
Abstract:Objectives: This study aimed to present the Asia-Pacific consensus on long-term and sequential therapy for osteoporosis, offering evidence-based recommendations for the effective management of this chronic condition. The primary focus is on achieving optimal fracture prevention through a comprehensive, individualized approach. Methods: A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti-osteoporosis medication goals, first-line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and antiresorptive agents in sequential therapy approaches. Results: The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first-line treatment for individuals at very high fracture risk and transitioning to antiresorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for individuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication-related complications, proposing alternatives instead of discontinuation of treatment. Conclusions: This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision-making and the incorporation of country-specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia-Pacific region, contributing to the ongoing evolution of osteoporosis management.